Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489405 | 0.83 | DRD4 (0.54) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL3489408 | 0.81 | DRD4 (0.53) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL21408106 | 0.79 | CA12 (0.54) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL6558520 | 0.76 | CA1 (0.51) | CA12CA1CA2CA9 | |
| SCHEMBL6589802 | 0.76 | CA1 (0.66) | KMT2AMEN1TDP1CA12CA1 | |
| SCHEMBL556793 | 0.76 | MEN1 (0.64) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL18995754 | 0.76 | SIGMAR1 (0.63) | DRD2DRD3 | |
| SCHEMBL6277903 | 0.75 | ALDH1A1 (0.47) | MAPTCA12CA2CA9 | |
| SCHEMBL19375072 | 0.75 | DRD4 (0.58) | DRD4DRD2DRD3KMT2AMEN1 | |
| SCHEMBL6422921 | 0.75 | KMT2A (0.63) | DRD4DRD2DRD3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015069441-A1 | PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-8905534-B2 | Ink composition and image forming method | FUJIFILM CORPORATION (JP) | 2014-12-09 | — | — | US | disclosed |
| US-20140132685-A1 | INK COMPOSITION AND IMAGE FORMING METHOD | FUJIFILM CORPORATION (JP) | 2014-05-15 | — | — | US | disclosed |
| EP-0610958-B1 | Intermediates in the preparation of 4-oxoquinoline-3-carboxylic acid derivatives | UBE INDUSTRIES (JP) | 2001-10-04 | — | — | EP | disclosed |
| EP-0352123-B1 | 4-Oxoquinoline-3-carboxylic acid derivatives, their preparation and their use | UBE INDUSTRIES (JP) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272645-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | DRD4 4350/4885DRD2 3798/4885DRD3 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.